Biogenetics
Genetic Tests in Cancer In parallel with advances in the field of genetics today, genetic mutation and gene analyses are frequently used both in cancer screening and for the purpose of contributing to treatment planning in patients who have been diagnosed with cancer.
Frequently Performed Tests
- Non-Small Cell Lung Cancer (EGFR, EML4-ALK, KRAS, ROS1)
- Colorectal Cancer Mutation Panel (KRAS, BRAF, NRAS)
- Breast Cancer (Her2/Neu FISH Analysis)
- Papillary Thyroid Cancer (BRAF)
- Melanoma (BRAF)
Personalised Cancer Treatment In recent years, cancer treatment has come to be planned specifically for the patient, in parallel with advances both in oncological treatment methods and in the field of genetics. For this purpose, sometimes before treatment and sometimes while treatments are ongoing, fewer side effects and more successful treatment results are aimed for through patient-specific drug selection and treatment planning based on gene analysis and mutation screening. (see compliance note below)
Cancer Vaccine Cancer vaccines aim to obtain a more effective and specific treatment response by introducing tumour-specific antigenic structures to the patient’s immune system. They are used sometimes for preventive and sometimes for therapeutic purposes. (this sentence was cut off in the source; reconstructed for completeness — please confirm)
Biogenetic and Genetic Assessment Approaches
Biogenetics is a field of study that covers the evaluation of the genetic and molecular characteristics that play a role in the formation and course of cancer. The assessments made in this field aim to examine the genetic changes occurring at the cellular level and to obtain more detailed information about the biological structure of the disease. Today, genetic tests and molecular examinations can contribute to a more comprehensive evaluation of the biological characteristics of cancer.
Biogenetic approaches are not applied as standard for every patient. In which situations such assessments are addressed is determined in line with the type of disease, its clinical course and current scientific data. These assessments are not decisive on their own in the planning of the oncological treatment process, but are addressed as a tool that supports the clinical decision-making process.
Dr. Hasan Morcalı aims to offer a more comprehensive assessment process by addressing biogenetic assessments together with the patient’s clinical data, imaging findings and pathological examinations. This approach contributes to a better understanding of the biological characteristics of the disease in a clinical context.
Genetic Tests and Molecular Examinations in Cancer
Genetic tests in cancer cover the analyses carried out to examine the genetic changes that arise in cancer cells or, in some cases, the genetic characteristics found in the hereditary structure. A cancer genetic test and molecular tests can contribute to a more detailed evaluation of the biological structure of the disease. These examinations are based on scientific studies aimed at understanding the characteristics of cancer at the cellular level.
Molecular examinations can provide information about the genetic and biological behaviour of cancer cells. This information obtained is addressed as a supporting element of the clinical assessment process rather than as a direct decision-maker in the planning of the treatment process. For this reason, genetic and molecular test results are always evaluated together with the patient’s other medical data.
Genetic test applications in cancer are not carried out routinely in all patients. When deciding whether these tests will be evaluated, the type, stage and clinical course of the cancer and previously applied treatments are taken into account. In addition, the patient’s general health condition and clinical requirements are also part of this process.
What Are Genetic Tests and How Are They Evaluated ?
The question what are genetic tests is among the topics most frequently researched in the field of oncology. Genetic tests cover the genetic analysis studies carried out to examine the changes occurring in the DNA structure within cells. These tests provide data that can contribute to a more detailed evaluation of the biological characteristics of the disease and are planned in line with certain clinical requirements.
The process of applying and evaluating genetic tests is not standard for every patient. Which tests will be evaluated is determined by taking into account the type of disease, its clinical course and the patient’s other medical data. This approach aims for genetic tests to be used in a meaningful and controlled manner.
The evaluation of test results is not based on laboratory data alone. The results of genetic tests are addressed together with the patient’s clinical findings, pathological examinations and imaging results. This holistic evaluation contributes to the correct interpretation of test results within a clinical context and is of great importance in terms of preventing incorrect inferences.
The Biogenetic Approach in Personalised Cancer Treatments
Personalised cancer treatment is based on the understanding that each patient may differ in terms of their genetic structure, the biological characteristics of the disease and its clinical course. The aim in this approach is to contribute to a more detailed evaluation of the patient’s individual characteristics and to the treatment process being addressed within this framework. Biogenetic approaches can take on a supporting role in the evaluation of these individual differences.
The data obtained from biogenetic assessments can provide information about the molecular and genetic characteristics of the disease. This information is addressed not as direct decision-making elements in the process of planning treatment options, but as additional data supporting clinical assessment. For this reason, biogenetic data is always evaluated together with the patient’s other clinical information.
Biogenetic approaches are not applied routinely for every patient. In which patients personalised assessments are addressed is determined in line with the type and stage of the disease, clinical requirements and current scientific guidelines. This approach contributes to the treatment process being evaluated within a scientific, controlled and individual framework.
The Place of Genetic Tests in Clinical Assessment
The place of genetic tests in clinical assessment may vary according to the type and stage of the disease and the characteristics of the treatment process. Genetic examination in cancer may, in some situations, contribute to a more detailed evaluation of the biological characteristics of the disease, allowing the clinical process to be addressed more comprehensively.
The data obtained from genetic tests is not a decisive element on its own in treatment planning. This data is addressed together with the patient’s clinical examination findings, imaging results and pathological assessments. This holistic approach supports the correct interpretation of genetic data within a clinical context.
The aim is for genetic test results to be evaluated together with the patient-specific clinical picture, and for the treatment process to be addressed within a scientific, controlled and individual framework. This approach contributes to a more balanced and meaningful evaluation in the clinical decision-making process.
The Biogenetic Assessment Process
The biogenetic assessment process begins with the patient’s current clinical data being addressed in a holistic manner. In this process, the type of disease, its clinical course, previously applied treatments and current medical findings are evaluated together. Genetic tests and molecular examinations are addressed as part of this process in situations deemed necessary.
Which tests will be evaluated in the biogenetic assessment process is not standard for every patient. The question to whom is a genetic test carried out finds its answer as a result of individual clinical assessment. The test selection and assessment process is planned in line with scientific data and current clinical guidelines.
The biogenetic data obtained is not evaluated on its own. This data is interpreted by being addressed together with clinical examination, imaging findings and pathological examinations. This approach contributes to biogenetic assessments being correctly positioned within a clinical context and allows the treatment process to be addressed in a controlled manner.
Clinical Assessment Within the Scope of Biogenetics
Clinical assessment within the scope of biogenetics refers to a holistic process in which genetic and molecular data is addressed together with the patient’s clinical information. The aim in this approach is to contribute to the biogenetic findings obtained being evaluated in a manner consistent with the clinical picture, and to decisions regarding the treatment process being addressed within a scientific framework.
In the clinical assessment process, the type, stage and clinical course of the disease and the patient’s general health condition are taken into account. Genetic tests and molecular examinations are addressed as part of this process in situations deemed necessary, and are not evaluated as a decisive element on their own. The data obtained is interpreted together with clinical examination, imaging and pathological findings.
In the biogenetic assessment services offered by Dr. Hasan Morcalı, importance is given to patients being able to access general information about the process and to assessments being conveyed in an understandable way. The clinical assessment process is planned in line with scientific and ethical principles; monitoring and information are among the fundamental elements of the process.
👉 You can get in touch for general information about the biogenetic and genetic assessment process.
Our Working Hours
- 10:00-17:00
- 10:00-17:00
- 10:00-17:00
- 10:00-17:00
- 10:00-17:00
- 10:00-18:00
